Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.

about

Effects of Deferoxamine on Leukemia In Vitro and Its Related Mechanism

P2860

Q58699827-D0296300-AB64-4611-9D08-21C0E0B67781

P2860

Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.

Item

http://www.wikidata.org/entity/Q38763826

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Deferasirox has strong anti-le ...... eukemia effect of doxorubicin.

@en

type

Item

label

Deferasirox has strong anti-le ...... eukemia effect of doxorubicin.

@en

prefLabel

Deferasirox has strong anti-le ...... eukemia effect of doxorubicin.

@en

P1476

Deferasirox has strong anti-le ...... eukemia effect of doxorubicin.

@en

P2093

Chaio-Lin Lin

http://www.w3.org/2001/XMLSchema#string

Chiu-Che Feng

http://www.w3.org/2001/XMLSchema#string

Hsin-Ting Lin

http://www.w3.org/2001/XMLSchema#string

Hsu-Chen Cheng

http://www.w3.org/2001/XMLSchema#string

Su-Peng Yeh

http://www.w3.org/2001/XMLSchema#string

Wen-Jyi Lo

http://www.w3.org/2001/XMLSchema#string

Yu-Chien Chang

http://www.w3.org/2001/XMLSchema#string

Yu-Ting Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

The role of iron and reactive oxygen species in cell death.

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.

Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.

Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.

HFE C282Y homozygotes are at increased risk of breast and colorectal cancer

P304

1-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1280604

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28140713

http://www.w3.org/2001/XMLSchema#string

Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.

about

P2860

P2860

Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698